Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28420314 | 0.84 | LMNA (0.55) | RECQLLMNAPKMGAACA2 | |
| SCHEMBL7241372 | 0.80 | CA12 (0.39) | CA12CA9RECQLLMNAPKM | |
| SCHEMBL21389077 | 0.79 | CA1 (0.35) | CA12CA9CA2CA1TSHR | |
| SCHEMBL21389092 | 0.79 | CA1 (0.35) | CA12CA9CA2CA1TSHR | |
| SCHEMBL6571599 | 0.79 | CA12 (0.39) | CA12CA9RECQLLMNAPKM | |
| SCHEMBL12069014 | 0.79 | SCN9A (0.34) | CA12CA9CA2CA1TSHR | |
| SCHEMBL12071190 | 0.79 | SCN9A (0.34) | CA12CA9CA2CA1TSHR | |
| SCHEMBL1724563 | 0.79 | SCN9A (0.34) | CA12CA9CA2CA1TSHR | |
| SCHEMBL11130899 | 0.77 | TSHR (0.41) | CA12CA9LMNACA2CA1 | |
| SCHEMBL28558305 | 0.77 | TSHR (0.41) | CA12CA9LMNAGAACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | CA12 4199/4885CA9 2993/4885RECQL 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.